Emmes
Emmes is a PE-backed full-service clinical research organization founded in 1981, serving biopharmaceutical, government, non-profit, and academic clients across rare disease, vaccines, ophthalmology, neuroscience, and cell & gene therapy. With ~5,500 employees, a proprietary Veridix AI-powered eClinical platform, and global operations in the US, UK, and Germany, it manages 32,000 clinical trial sites.
- Company typePrivate
- Founded1981
- HeadquartersRockville, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Emmes does
Emmes is a privately held, PE-backed full-service clinical research organization (CRO) founded in 1981 and headquartered in Rockville, Maryland, with approximately 5,500 employees across the United States, the United Kingdom, and Germany. The company serves biopharmaceutical companies, government agencies, non-profit organizations, and academic institutions, with therapeutic specializations in rare disease, vaccines and infectious disease, ophthalmology, clinical neuroscience, cell and gene therapy, and government research. Emmes provides end-to-end clinical services spanning biostatistics, clinical data management, clinical research services, clinical trial management, global regulatory affairs, and pharmacovigilance and medical monitoring, and reports relationships with 15 of the top 25 biopharma companies over the past three years alongside a 98% client retention rate.
The company's technology backbone is the Veridix eClinical platform, branded as a native digital and AI specialty CRO offering. Veridix comprises modular components including electronic data capture (EDC), decentralized clinical trials (DCT), Health Navigator, randomization and trial supply management (RTSM), eCOA/ePRO, and GlobalTrace, together with named AI agents for biostatistics and analysis, data management, and document authoring, plus the VERA AI reporting agent. Emmes scales this platform across 32,000 clinical trial sites and 30M+ electronic case report form pages, and holds ISO 9001 certification.
Emmes generates revenue through service contracts with biopharma, government, non-profit, and academic clients under a quote-based, B2B enterprise pricing model, distributed via direct enterprise field sales and an RFP submission process under a dedicated Chief Commercial Officer. The company is owned by Behrman Capital (with Delancey Street Partners as a co-investor from the 2019 round) and has executed seven acquisitions since 2019 — Neox CRO (2020), Orphan Reach (2021, UK rare disease), Institut Dr. Schauerte (2021, Germany, real-world evidence), Casimir (2022, US rare disease), Clinical Edge (2022, ophthalmic certification), Essex Management (2023, health informatics), and VaxTrials (2023, vaccines) — to build specialty depth, geographic reach, and bioinformatics capability.
Emmes firmographics
Firmographics- Name
- Emmes
- Legal name
- The Emmes Company, LLC
- Website
- https://emmes.com
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Emmes is a PE-backed full-service clinical research organization founded in 1981, serving biopharmaceutical, government, non-profit, and academic clients across rare disease, vaccines, ophthalmology, neuroscience, and cell & gene therapy. With ~5,500 employees, a proprietary Veridix AI-powered eClinical platform, and global operations in the US, UK, and Germany, it manages 32,000 clinical trial sites.
- Ownership category
- akta.pro rank
Emmes industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- All Other Professional, Scientific, and Technical Services (54199), Professional, Scientific, and Technical Services (54), Computer Systems Design and Related Services (54151)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Sample Collection & Site Phlebotomy Services (HLAGACAJ)
- akta.pro secondary industries
- eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)
Keywords
Where Emmes is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Emmes business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- CRO Services: Full-service clinical research organization providing end-to-end clinical trial services including biostatistics, clinical data management, clinical research services, trial management, regulatory affairs, and pharmacovigilance. Revenue generated through service contracts with biopharma companies, government agencies, non-profits, and academic institutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Emmes product offering
Product offeringCore offering
Emmes is a global full-service contract research organization that delivers end-to-end clinical trial services — including biostatistics, clinical data management, clinical research services, clinical trial management, global regulatory affairs, and pharmacovigilance & medical monitoring — to biopharmaceutical, government, non-profit, and academic partners. It supports these services with a proprietary technology and AI platform called Veridix, which provides an eClinical Platform (EDC, DCT, RTSM, eCOA/ePRO, Health Navigator), AI Agents (biostatistics, data management, document authoring), GlobalTrace site/trial oversight, and VERA analytics & reporting.
Product overview
Emmes is a full-service Clinical Research Organization (CRO) operating as 'The Industry's First Native Digital and AI Specialty CRO.' The company offers an integrated portfolio combining traditional clinical research services with a proprietary technology platform called Veridix. The Veridix eClinical Platform provides modular solutions including EDC, Decentralized Clinical Trials (DCT), Health Navigator, RTSM, eCOA/ePRO, and GlobalTrace, supported by AI Agents for biostatistics, data management, and document authoring. Emmes' clinical services span biostatistics, clinical data management, clinical research services, clinical trial management, regulatory affairs, and pharmacovigilance. The company has expanded through strategic acquisitions including Casimir (rare diseases), Orphan Reach (UK rare disease CRO), Clinical Edge (ophthalmic training), Institut Dr. Schauerte (real-world evidence), and Essex Management (health informatics). Emmes specializes in vaccines and infectious diseases, ophthalmology, clinical neuroscience, rare disease, cell and gene therapy, and government research.
Differentiator
Problem solved
Functional benefit
Brands
- Veridix: Technology and AI division offering eClinical Platform, EDC, Decentralized Clinical Trials (DCT), RTSM, eCOA/ePRO, AI Agents (Biostats and Analysis Agent, Data Management Agent, Document Authoring), GlobalTrace, and Analytics & Reporting tools.
- GlobalTrace
- VERA
Products and services
- Emmes CRO Clinical Services Full-service clinical research organization offerings including Biostatistics, Clinical Data Management, Clinical Research Services, Clinical Trial Management, Global Regulatory Affairs, and Pharmacovigilance & Medical Monitoring, delivered to biopharmaceutical, government, non-profit, and academic partners.
- Veridix eClinical Platform Comprehensive electronic clinical platform supporting the full trial lifecycle, integrating Electronic Data Capture (EDC), Decentralized Clinical Trials (DCT), Randomization and Trial Supply Management (RTSM), eCOA/ePRO, and Health Navigator for patient and site engagement.
- Veridix AI Agents Suite of AI-powered agents for clinical research workflows, including the Biostats and Analysis Agent, the Data Management Agent, and the Document Authoring Agent, designed to automate biostatistics, data management, and clinical document creation.
- GlobalTrace Global site and clinical trial management tracking system for oversight of multi-site, multi-country clinical trials.
- VERA AI Reporting & Analytics (Clinical Pipelines) AI-powered reporting and analytics offering for clinical trials, comprising the VERA AI Reporting Agent and Clinical Pipelines analytics module for pipeline-level reporting.
Quantifiable outcome
- 98% client retention rate demonstrates exceptional quality and customer satisfaction
- +4 more outcomes
Companies that use Emmes
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Emmes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature12 records
Emmes partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Essex ManagementcoreAcquired by Emmes in March 2023, Essex Management is a health informatics and bioinformatics consultancy. The acquisition added more than 100 employees and aims to expand Emmes' services to government agencies and biopharma clients, leveraging Essex's technology and expertise.
- Clinical EdgecoreAcquired by Emmes in September 2022, Clinical Edge is a provider of ophthalmic certification and training services. The acquisition strengthens Emmes' ophthalmology credentials and expands its international reach, creating a leader in ophthalmic certification with focus on standardization and decentralization of training services.
- CasimircoreAcquired by Emmes in March 2022, Casimir is a U.S.-based CRO specializing in rare diseases. The deal bolsters Emmes' focus on rare disease research and expands its clinical outcomes technology, enhancing rare and orphan disease research capabilities particularly in neurodegenerative and neuromuscular conditions.
- Institut Dr. SchauertecoreAcquired by Emmes in December 2021, Institut Dr. Schauerte is a Munich-based CRO specializing in real-world evidence research. The acquisition expands Emmes' presence in Germany and enhances its digital capabilities with new RWE tools and data systems.
- Orphan ReachcoreAcquired by Emmes in May 2021, Orphan Reach is a UK-based CRO specializing in rare disease research. The acquisition strengthens Emmes' global footprint and expertise in orphan and rare disease trials, with Orphan Reach having conducted 60 rare disease clinical trials and serving over 50 biopharma clients worldwide.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Emmes competitors and assessment
Company assessmentDirect peers
- Parexel International: PE-owned (EQT/Goldman Sachs) full-service CRO of comparable mid-to-large scale. Closely comparable on business model (full-service clinical research for biopharma), therapeutic breadth, and PE-backed growth strategy, making it the most direct peer for Emmes.
- Syneos Health: Large PE-owned CRO (Elliott/Veritas/Patient Square) offering full-service clinical development and commercialization services. Directly comparable as a PE-backed full-service CRO serving top biopharma with similar therapeutic breadth.
- Worldwide Clinical Trials: Mid-sized, PE-owned ( Kohlberg & Company) global CRO with strong rare disease, neuroscience, and cardiometabolic expertise. Highly comparable to Emmes in scale, therapeutic specialization, and PE-backed positioning.
- Medpace: Mid-to-large full-service CRO focused on small and mid-sized biopharma with strong therapeutic expertise. Comparable in operating model and customer base, though publicly listed and at larger scale.
- Premier Research: PE-owned (BC Partners) mid-sized CRO with strong rare disease, oncology, and pediatric focus. Comparable in scale, therapeutic specialization, and PE-backed growth orientation.
Broad incumbents
- IQVIA: Largest global CRO and life sciences technology company. Emmes competes against IQVIA for large full-service biopharma engagements, but IQVIA operates at far greater scale and breadth across R&D services, technology, and data.
- ICON plc: Top-3 global CRO formed via PRA Health Sciences combination. Competes head-to-head with Emmes for biopharma full-service work, but at materially larger scale and with deeper therapeutic and geographic coverage.
- Labcorp (incl. Covance): Diversified diagnostics and CRO (Covance) business. Overlaps with Emmes on clinical development services but operates a much broader portfolio including central labs, diagnostics, and drug development.
- Charles River Laboratories: Large life sciences services company spanning research models, discovery, and CDMO/CRO services. Adjacent comparable on CRO services and therapeutic breadth, with significantly larger scale and public-market profile.
Emerging players
- Clario (formerly CRF Health / ERT merged): PE-owned (Bain Capital/GTCR) eClinical technology provider specializing in eCOA, cardiac safety, and imaging. Comparable to Emmes' Veridix eClinical platform strategy and eCOA/ePRO offering, but focused on technology rather than full-service CRO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Emmes social profiles
Digital presenceEmmes compliance and trust
Trust signalCompliance1 record
Emmes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emmes leadership team
Management profileNumber of profiles
Profiles8 records
Emmes subsidiaries and ownership
Company hierarchySubsidiaries5 records
Emmes funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emmes M&A and investment
M&A and investmentM&A7 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emmes
What does Emmes do?
Emmes is a global full-service contract research organization that delivers end-to-end clinical trial services — including biostatistics, clinical data management, clinical research services, clinical trial management, global regulatory affairs, and pharmacovigilance & medical monitoring — to biopharmaceutical, government, non-profit, and academic partners. It supports these services with a proprietary technology and AI platform called Veridix, which provides an eClinical Platform (EDC, DCT, RTSM, eCOA/ePRO, Health Navigator), AI Agents (biostatistics, data management, document authoring), GlobalTrace site/trial oversight, and VERA analytics & reporting.
Is Emmes a public or private company?
Emmes is a private company. It is classified as private equity controlled and is currently operating.
When was Emmes founded?
Emmes was founded in 1981. It employs 1,001 to 5,000 people.
Where is Emmes based?
Emmes is headquartered in Rockville, United States, in the North America region.
How does Emmes make money?
One revenue line is on record: CRO Services.
Who are Emmes's main competitors?
Direct peers on record are Parexel International, Syneos Health, Worldwide Clinical Trials, Medpace and Premier Research. Broad incumbents are IQVIA, ICON plc, Labcorp (incl. Covance) and Charles River Laboratories. Clario (formerly CRF Health / ERT merged) is listed as an emerging player.
Does Emmes have an API?
No public API is recorded for Emmes.
What industry is Emmes in?
Emmes's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGACAJ, Clinical Trial Sample Collection & Site Phlebotomy Services, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 54199 and its SIC code is 8000.